{"entity":{"id":"nct07072728","kind":"trial","name":"Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder","aka":[],"tldr":"A phase 2 trial of Psilocybin therapy in endometrial cancer, prostate cancer, gastric & gastro-oesophageal junction cancer, melanoma and pancreatic ductal adenocarcinoma, run by Psyence Australia Pty Ltd, now recruiting.","summary":"Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder is a phase 2 interventional study registered as NCT07072728 by Psyence Australia Pty Ltd, with 87 participants planned, started 2025-10-01 and due to reach its primary completion in 2026-12-30. Interventions recorded: Psilocybin therapy.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07072728","url":"https://clinicaltrials.gov/study/NCT07072728"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["endometrial","prostate","gastric","melanoma","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07072728","phase":"2","setting":"A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer.","sponsor":"Psyence Australia Pty Ltd","enrolled":87,"outcomes":[]},"route":"/trials/nct07072728/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}]}}